Literature DB >> 8798178

Progress in antisense therapeutics.

S T Crooke1.   

Abstract

Mesh:

Substances:

Year:  1996        PMID: 8798178     DOI: 10.1002/(SICI)1098-1128(199607)16:4<319::AID-MED2>3.0.CO;2-#

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


× No keyword cloud information.
  6 in total

1.  Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.

Authors:  P Lorenz; T Misteli; B F Baker; C F Bennett; D L Spector
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

2.  Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies.

Authors:  P Lorenz; B F Baker; C F Bennett; D L Spector
Journal:  Mol Biol Cell       Date:  1998-05       Impact factor: 4.138

3.  Structural characteristics of 2'-O-(2-methoxyethyl)-modified nucleic acids from molecular dynamics simulations.

Authors:  K E Lind; V Mohan; M Manoharan; D M Ferguson
Journal:  Nucleic Acids Res       Date:  1998-08-15       Impact factor: 16.971

Review 4.  In vivo and in vitro studies of antisense oligonucleotides - a review.

Authors:  Anna Kilanowska; Sylwia Studzińska
Journal:  RSC Adv       Date:  2020-09-17       Impact factor: 4.036

Review 5.  The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.

Authors:  Traian V Chirila; Piroska E Rakoczy; Kerryn L Garrett; Xia Lou; Ian J Constable
Journal:  Biomaterials       Date:  2002-01       Impact factor: 12.479

Review 6.  Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target.

Authors:  Yan Jia; Vitaly Polunovsky; Peter B Bitterman; Carston R Wagner
Journal:  Med Res Rev       Date:  2012-04-11       Impact factor: 12.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.